Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Munoz

Showing results (111-120 of 169) with videos related to

Pageof 17
Sort By:
American Journal of Hematology|November 11, 2023
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approachOmran Saifi, Scott C Lester, William G Breen, et al.
The Lancet. Oncology|May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 studyHervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Blood|March 18, 2020
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.
American Journal of Hematology|December 30, 2025
Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo ClinicAhmed Alnughmush, Suheil Albert Atallah-Yunes, Tamer Hellou, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
Transplantation and Cellular Therapy|July 16, 2022
Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell TherapyMadiha Iqbal, Radhika Bansal, Farah Yassine, et al.
British Journal of Haematology|June 17, 2025
Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphomaKevin Chung, Lay She Ng, Claire I Yee, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
Pageof 17

Showing results (111-120 of 169) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|November 11, 2023
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approachOmran Saifi, Scott C Lester, William G Breen, et al.
The Lancet. Oncology|May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 studyHervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Blood|March 18, 2020
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.
American Journal of Hematology|December 30, 2025
Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo ClinicAhmed Alnughmush, Suheil Albert Atallah-Yunes, Tamer Hellou, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
Transplantation and Cellular Therapy|July 16, 2022
Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell TherapyMadiha Iqbal, Radhika Bansal, Farah Yassine, et al.
British Journal of Haematology|June 17, 2025
Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphomaKevin Chung, Lay She Ng, Claire I Yee, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
Pageof 17